Home > Insider Trading > Filing (0001104659-20-138021)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1718108	Surface Oncology Inc.	SURF	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1671207	Atlas Venture Associates Ix, Llc	56 Wareham Street, Floor 3 Boston MA 02118	No	No	Yes	No
1671208	Atlas Venture Associates Ix, L.p.	56 Wareham Street, Floor 3 Boston MA 02118	No	No	Yes	No
1671219	Atlas Venture Fund Ix, L.p.	56 Wareham Street, Floor 3 Boston MA 02118	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-12-17	1,700,000	$8.10	2,945,453	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of Atlas IX, AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed to an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The high, low and average for the shares sold were all $8.10. Each of the Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
Represents shares held directly by Atlas IX. The general partner of the Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by the Atlas IX except to the extent of its pecuniary interest therein, if any.
This Amendment to the Form 4 originally filed by the Reporting Persons on December 21, 2020 is filed to amend the share price in Table I from $18.10 to $8.10.